



LITERATURA

1. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2006;50(6):1953-1958.
2. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. *Curr Med Res Opin*. 2015;31(4):707-721.
3. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. *Antimicrob Agents Chemother*. 1985;28(1):107-112.
4. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. *J Med Chem*. 2010;53(5):1898-1916.
5. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid killing of *Acinetobacter baumannii* by polymyxins is mediated by a hydroxyl radical death pathway. *Antimicrob Agents Chemother*. 2012;56(11):5642-5649.
6. Ehrentauf SF, Muenster S, Kreyer S et al. Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks. *Microorganisms*. 2020;8(3):415.
7. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. *J Cyst Fibros*. 2004;3(1):23-28.
8. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. *N Engl J Med*. 2007;357(22):2310-2311.
9. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. *Ann Intensive Care*. 2016;6(1):26.
10. Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Anesthesiology*. 2012;117(6):1335-1347.
11. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. *Antimicrob Agents Chemother*. 2008;52(9):3047-3051.
12. Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. *Antimicrob Agents Chemother*. 2012;56(12):6432-6433.
13. Bihan K, Zahr N, Becquemin MH et al. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. *J Antimicrob Chemother*. 2018;73(6):1639-1646.
14. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. *Thorax*. 1997;52(7):656-658.
15. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. *Br Med J (Clin Res Ed)*. 1981;283(6302):1285-1287.
16. Boisson M, Jacobs M, Grégoire N et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. *Antimicrob Agents Chemother*. 2014;58(12):7331-7339.
17. Tsuji BT, Pogue JM, Zavascki AP et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019;39(1):10-39.
18. Colomycin. Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv [online]. [cit. 2022-01-19]. Dostupné z: <https://www.sukl.cz>.
19. Abdulla A, van Leeuwen RWF, de Vries Schultink AHM. Stability of colistimethate sodium in a disposable elastomeric infusion device. *Int J Pharm*. 2015;486:367-369.
20. Post TE, Kamerling IMC, van Rossen RCJM et al. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. *European Journal of Hospital Pharmacy*. 2018;25:337-339.
21. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant *Acinetobacter baumannii* bacteraemia with continuous intravenous infusion of colistin. *Scand J Infect Dis*. 2005;37(2):142-145.
22. Kassamali Z, Curello J, Gregson A. Comparison of continuous versus intermittent intravenous infusion of colistimethate sodium (colistin) for treatment of carbapenem-resistant gram negative bacterial infections. 26th European Congress of Clinical Microbiology and Infectious Diseases. 2012, April 9-12. Amsterdam, Netherlands.
23. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. *Antimicrob Agents Chemother*. 2009;53(8):3430-3436.
24. Mohamed AF, Karaikos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. *Antimicrob Agents Chemother*. 2012;56(8):4241-4249.